| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
| Targets |
N-dodecanoyl-L-Homoserine lactone targets the LasR quorum sensing receptor in P. aeruginosa and other Gram-negative bacteria. LasR is a LuxR-type transcriptional regulator that, upon binding to C12-HSL, activates the expression of target genes involved in virulence, biofilm formation, and other population-dependent behaviors. The compound's long acyl chain (12 carbons) confers specificity for LasR over other quorum sensing receptors, such as RhlR. N-dodecanoyl-L-Homoserine lactone is a key signaling molecule in the P. aeruginosa quorum sensing hierarchy.
|
|---|---|
| ln Vitro |
One strategy to lessen bacterial pathogenicity and medication resistance is to interfere with intercellular communication or quorum sensing (QS) [1].
In vitro, N-dodecanoyl-L-Homoserine lactone is used to activate quorum sensing in P. aeruginosa and other bacteria. The compound induces the expression of LasR-regulated genes, including those encoding virulence factors such as elastase, protease, and exotoxin A. It also promotes biofilm formation and motility. In reporter strains, C12-HSL can be used to quantify LasR activity and screen for quorum sensing inhibitors. |
| ln Vivo |
In vivo, N-dodecanoyl-L-Homoserine lactone plays a critical role in the pathogenesis of P. aeruginosa infections. The compound's production in vivo regulates the expression of virulence factors that contribute to tissue damage and immune evasion. C12-HSL has also been shown to have immunomodulatory effects, affecting host immune responses. The compound is a key target for the development of quorum sensing inhibitors as a novel approach to treating P. aeruginosa infections.
|
| Enzyme Assay |
In vitro receptor binding assays for N-dodecanoyl-L-Homoserine lactone involve measuring its binding affinity to LasR. The assay is typically performed using recombinant LasR protein and a fluorescently labeled or radiolabeled ligand. The compound is incubated with the receptor and the labeled ligand, and the bound label is measured. The IC₅₀ and Ki values are calculated from the displacement curves. Functional activity is assessed using reporter gene assays.
|
| Cell Assay |
In vitro cellular experiments for N-dodecanoyl-L-Homoserine lactone are performed using P. aeruginosa cultures. Bacteria are grown in the presence of varying concentrations of the compound, and the expression of LasR-regulated genes is measured using reporter strains or qPCR. The effects of the compound on biofilm formation, motility, and virulence factor production are assessed using standard assays. These experiments are essential for characterizing the compound's biological activity.
|
| Animal Protocol |
In vivo animal studies for N-dodecanoyl-L-Homoserine lactone are conducted using mouse or rat models of P. aeruginosa infection. The compound is administered via intraperitoneal or subcutaneous injection, or directly to the site of infection. The effects on bacterial virulence, biofilm formation, and disease progression are assessed by monitoring survival, bacterial burden, and clinical signs of infection.
|
| ADME/Pharmacokinetics |
The pharmacokinetic properties of N-dodecanoyl-L-Homoserine lactone have not been extensively characterized. As a small, lipophilic molecule, it is expected to be rapidly absorbed and distributed, but it may be susceptible to hydrolysis and degradation in biological fluids. The compound's stability and half-life in vivo are likely to be short, limiting its utility for in vivo studies.
|
| Toxicity/Toxicokinetics |
The toxicity of N-dodecanoyl-L-Homoserine lactone has not been extensively characterized. As a bacterial signaling molecule, it is expected to have low toxicity in mammalian cells. However, high concentrations may have immunomodulatory effects. Standard safety precautions should be followed when handling this compound.
|
| References |
[1]. Borges A, et al. Furvina inhibits the 3-oxo-C12-HSL-based quorum sensing system of Pseudomonas aeruginosa and QS-dependent phenotypes. Biofouling. 2017 Feb;33(2):156-168.
|
| Additional Infomation |
(S)-N-dodecanoyl-HSL is an N-acyl amino acid. It has been reported that N-dodecanoyl-L-homoserine lactone exists in Cronobacter sakazakii, and relevant data are available for reference.
N-dodecanoyl-L-Homoserine lactone is a naturally occurring quorum sensing signal molecule used by P. aeruginosa. It activates the LasR receptor, regulating the expression of virulence factors, biofilm formation, and other population-dependent behaviors. C12-HSL is a key target for the development of quorum sensing inhibitors as a novel approach to treating P. aeruginosa infections. It is a valuable tool for studying bacterial cell-cell communication and pathogenesis. |
| Molecular Formula |
C16H29NO3
|
|---|---|
| Molecular Weight |
283.4064
|
| Exact Mass |
283.215
|
| CAS # |
137173-46-7
|
| PubChem CID |
10221437
|
| Appearance |
White to off-white solid powder
|
| Density |
1.005g/cm3
|
| Boiling Point |
485.84ºC at 760 mmHg
|
| Flash Point |
247.627ºC
|
| Vapour Pressure |
0mmHg at 25°C
|
| Index of Refraction |
1.477
|
| LogP |
3.729
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
20
|
| Complexity |
291
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O1C([C@]([H])(C([H])([H])C1([H])[H])N([H])C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)=O
|
| InChi Key |
WILLZMOKUUPJSL-AWEZNQCLSA-N
|
| InChi Code |
InChI=1S/C16H29NO3/c1-2-3-4-5-6-7-8-9-10-11-15(18)17-14-12-13-20-16(14)19/h14H,2-13H2,1H3,(H,17,18)/t14-/m0/s1
|
| Chemical Name |
N-[(3S)-2-oxooxolan-3-yl]dodecanamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~25 mg/mL (~88.21 mM)
H2O : < 0.1 mg/mL |
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5285 mL | 17.6423 mL | 35.2846 mL | |
| 5 mM | 0.7057 mL | 3.5285 mL | 7.0569 mL | |
| 10 mM | 0.3528 mL | 1.7642 mL | 3.5285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
